参考文献

［1］Beham AW，Schaefer IM，Schüler P，et al.Gastrointestinal stromal tumors［J］.Int J Colorectal Dis，2012，27（6）：689-700.

［2］Bamboat ZM，Dematteo RP. Updates on the management of gastrointestinalstromal tumors［J］.Surg Oncol Clin N Am，2012，21（2）：301-316.

［3］Lamba G，Gupta R，Lee B，et al.Current management and prognostic features for gastrointestinal stromal tumor（GIST）［J］.Exp Hematol Oncol，2012，1（1）：14.

［4］Pink D，Schoeler D，Lindner T，et al.Severe hypoglycemia caused by paraneoplastic production of IGF II in patients with advanced gastrointestinal stromal tumors：a report of two cases［J］.J Clin Oncol，2005，23（27）：6809-6811.(https://www.daowen.com)

［5］Heinrich MC，Corless CL，Duensing A，et al. Pdgfra activating mutations in gastrointestinal stromal tumors［J］.Science，2003，299（5607）：708-710.

［6］Blanke CD，Rankin C，Demetri GD，et al. PhaseⅢrandomized，intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase：S0033［J］.J Clin Oncol，2008，26（4）：626-632.

［7］Raut CP，Posner M，Desai J，et al.Surgical management of advanced gastrointestinal stromal tumors after treatment with targeted systemic therapy using kinase inhibitors［J］.J Clin Oncol，2006，24（15）：2325-2331.

［8］HakiméA，Le Cesne A，Deschamps F，et al.A role for adjuvant RFA in managing hepatic metastases from gastrointestinal stromal tumors（GIST）after treatment with targeted systemic therapy using kinase inhibitors［J］.Cardiovasc Intervent Radiol，2014，37（1）：132-139.